← back to search

Yinhua Liu

Qinhuangdao Second Hospital · CN
Area of research
Cancer Research · Oncology
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Colorectal Cancer Surgical Treatments, and Clinical practice guidelines implementation.
h-index
16
citations
870
works
124
NIH funding
primary concept
email

Recent publications

Flexible and sensitive pressure sensor with enhanced breathability for advanced wearable health monitoring
npj Flexible Electronics 2025cited by 19position: middledoi
Abstract PO2-04-02: Trends in Disparities and Transitions of target therapy in Patients With ERBB2 Positive Early Breast Cancer in China and the US, 2011 to 2021
Cancer Research 2024cited by 0position: middledoi
Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021
JAMA Network Open 2023cited by 27position: middledoi
A comparison between clinical decision support system and clinicians in breast cancer
Heliyon 2023cited by 6position: middledoi
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
Therapeutic Advances in Medical Oncology 2023cited by 4position: middledoi
Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
Infectious Diseases & Immunity 2023cited by 1position: middledoi
Disparities and Transitions of Early Breast Cancer in China and USA Over the Decade
SSRN Electronic Journal 2023cited by 0position: middledoi
A comparison between a clinical decision support system and clinicians with guidelines in breast cancer.
Journal of Clinical Oncology 2023cited by 0position: middledoi
A Comparison Between CSCO AI and Clinicians in Breast Cancer: A Double-Blind, Controlled Phase III Trial
SSRN Electronic Journal 2022cited by 0position: middledoi
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
EClinicalMedicine 2020cited by 51position: middledoi
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China
The Oncologist 2017cited by 46position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Zefei Jiang · University of Sydney8 papers (2017–2024)Jianbin Li · Nanchang University8 papers (2017–2024)Cuizhi Geng · Hebei Medical University5 papers (2017–2024)Shaohua Zhang · The University of Texas Southwestern Medical Center4 papers (2022–2023)Haibo Wang · Qingdao University4 papers (2017–2024)Zhenzhen Liu · Shandong Normal University3 papers (2023–2024)Li Ma · Johns Hopkins University Applied Physics Laboratory3 papers (2022–2023)Li Bian · Chinese Academy of Fishery Sciences3 papers (2022–2023)Ying Lin · Guangzhou University of Chinese Medicine2 papers (2023–2023)Yuee Teng · Henan Academy of Agricultural Sciences2 papers (2023–2023)Yongmei Yin · Sun Yat-sen University2 papers (2017–2023)Yunjiang Liu · Hebei Medical University2 papers (2023–2023)Feng Jin · Hebei University2 papers (2023–2023)Yang Yuan · Nanjing University of Chinese Medicine2 papers (2023–2023)Yiding Chen · Ministry of Education of the People's Republic of China2 papers (2023–2023)Ling Xin · Cardiff University2 papers (2022–2023)Yue Xiao · Jiangsu University2 papers (2023–2023)Qianjun Chen · Guangzhou University of Chinese Medicine2 papers (2023–2023)Qiang Lin · Hainan Normal University2 papers (2022–2023)Hua Yang · Chongqing University2 papers (2023–2023)